Arginase activity - a marker of disease status in patients with visceral leishmaniasis in Ethiopia

Autor: Markus Munder, Ellen I. Closs, Margaux Corset, Workagegnehu Hailu, Teklu Weldegebreal, Yifru Sisay, Camille Corset, Asrat Hailu, Manuel Modolell, Karina Corware, Yegnasew Takele, Pascale Kropf, Fabienne Tacchini-Cottier, Ingrid Müller, Tom Cloke, Tamrat Abebe
Jazyk: angličtina
Rok vydání: 2013
Předmět:
Male
CUTANEOUS LEISHMANIASIS
CD3 Complex
Neutrophils
medicine.medical_treatment
T-Lymphocytes
Biochemistry
Antigens
CD3

Immune tolerance
0302 clinical medicine
INFECTION
SUPPRESSOR-CELLS
Immune Response
PLASMA AMINO-ACIDS
0303 health sciences
L-ARGININE
T Cells
lcsh:Public aspects of medicine
PARASITOLOGY
Immunosuppression
11 Medical And Health Sciences
CANCER
3. Good health
Arginase
medicine.anatomical_structure
Infectious Diseases
Medicine
Leishmaniasis
Visceral

Biological Markers
Metabolic Pathways
Life Sciences & Biomedicine
Research Article
EXPRESSION
Adult
lcsh:Arctic medicine. Tropical medicine
Adolescent
lcsh:RC955-962
T cell
Immune Cells
030231 tropical medicine
Immunology
Biology
Arginine
Peripheral blood mononuclear cell
Microbiology
MECHANISMS
Immunomodulation
03 medical and health sciences
Young Adult
Immune system
Cutaneous leishmaniasis
Tropical Medicine
medicine
Immune Tolerance
ACTIVATED GRANULOCYTES
Humans
CYTOKINE PROFILES
030304 developmental biology
Science & Technology
Public Health
Environmental and Occupational Health

lcsh:RA1-1270
06 Biological Sciences
medicine.disease
Visceral leishmaniasis
Metabolism
Ethiopia
Biomarkers
Zdroj: PLoS Neglected Tropical Diseases, Vol 7, Iss 3, p e2134 (2013)
PLoS Neglected Tropical Diseases, vol. 7, no. 3, pp. e2134
PLoS neglected tropical diseases
PLoS Neglected Tropical Diseases
ISSN: 1935-2727
Popis: The underlying mechanisms resulting in the profound immune suppression characteristic of human visceral leishmaniasis (VL) are not fully understood. Here, we tested the hypothesis that arginase, an enzyme associated with immunosuppression, is higher in patients with VL and contributes to impaired T cell responses. We recruited patients with VL before and after treatment and healthy controls and measured the arginase metabolism in the blood of these individuals. Our results show that arginase activity is significantly higher in the blood of patients with active VL as compared to controls. These high levels of arginase decline considerably once the patients are successfully treated. We identified the phenotype of arginase-expressing cells among PBMCs as neutrophils and show that their frequency was increased in PBMCs of patients before treatment; this coincides with reduced levels of L-arginine in the plasma and decreased expression levels of CD3ζ in T cells.
Author Summary Leishmaniases, a group of diseases caused by a parasite, Leishmania, belong to the most neglected tropical diseases: they are mainly found in low-income countries and affect the poorest populations. These parasites infect cells of the immune system called macrophages, which can kill the intracellular parasites when they receive the right signals from other cells of the immune system, the lymphocytes. During the active phase of visceral leishmaniasis, it has been shown that lymphocytes lose their capacity to instruct the macrophages to kill the intracellular parasites. Here, we show that the levels of an enzyme, arginase, are significantly increased in the blood of patients with visceral leishmaniasis, but decrease to the same levels as those of healthy controls following successful treatment. Arginase has the capacity to deplete an amino acid, L-arginine, which is crucial for the activation of lymphocytes. Indeed, our results show that the levels of this amino acid are considerably decreased in patients with visceral leishmaniasis. Our results suggest that during the active phase of visceral leishmaniasis, increased arginase results in the depletion of L-arginine, which is responsible for the incapacity of lymphocytes to send the adequate signals to the macrophages.
Databáze: OpenAIRE